Dr Allen's Device is the only safe treatment to reduce the size of an enlarged prostate gland due to benign prostatic hyperplasia (BPH), treating lower urinary tract symptoms (LUTS).
BPH is not cancer and primarily requires careful and safe treatment that does not interfere with men’s daily life. Men should note that BPH is diagnosed in about 50% of men over 50. The incidence of prostate enlargement increases with age, reaching 90 percent in men over 80.
The effectiveness and safety of Dr Allen’s Device for Prostate Treatment has been proven in the controlled clinical trials. According to a scientific article: “Innovative Thermobalancing therapy and Dr Allen's Device for the first time employ body energy to treat chronic prostatic diseases effectively”, published in the leading medical journal, this device reduces the abnormal size of the enlarged prostate without side effects.
Standard BPH treatments drugs and surgeries are risky
The standard treatment options for BPH are medications and surgery, which have serious side effects, including sexual and erectile dysfunction, impotence, and diabetes. These new health conditions can cause additional mental problems and depression.
A medical article published in September 2021, “The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction” states that most treatments for LUTS associated with BPH result in ejaculatory dysfunction (ED), manifest as anejaculation, decreased ejaculation, retrograde ejaculation, painful ejaculation or premature ejaculation, and male fertility.
After BPH surgery, patients attach great importance to maintaining their sexual function, which can be irreversibly impaired.
Out-of-hospital use of Dr Allen’s Device is side effects free
Dr Allen’s Device has been registered with the Medical Regulatory Healthcare Agency in Great Britain since 2010, as a class 1 medical device that cannot harm. So, its safety is confirmed over the decade. This exclusive device and Thermobalancing therapy received a patent issued by the US Patent and Trademark Office, confirming the uniqueness of this treatment for BPH.
The Aging Male journal published the article “Use of Thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology”, which explains that Dr Allen’s Device treats the cause of BPH by improving blood circulation in the affected prostate, reducing enlargement of the prostate and urinary symptoms dramatically.
Fine Treatment produces and distributes Dr Allen’s Device
Thermobalancing treatment is used by people at home for over ten years successfully. The use of Dr Allen’s Device at home is important as it protects men from visiting clinics and hospitals, which are the most dangerous place for contracting a coronavirus infection.
Fine Treatment https://finetreatment.com/ manufactures Dr Allen’s Devices in the United Kingdom and makes them available worldwide, with free international delivery. Thousands of Fine Treatment’s customers with LUTS due to BPH across 100 countries have already benefited from this powerful and safe Thermobalancing therapy without BPH drugs and surgeries.
This article does not necessarily reflect the opinions of the editors or the management of EconoTimes


Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Google Secures Pentagon AI Deal for Classified Projects 



